SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
复制标题
DOI：
10.1593/tlo.09109
复制
发表时间：
2009-05-01
影响因子：
5
通讯作者：
Soon-Shiong, Patrick
中科院分区：
文献类型：
--
作者：
Desai, Neil;Trieu, Vuong;Soon-Shiong, Patrick
在头颈癌中，表达上调是一个预后不良的因素。据推测，由于SPARC-白蛋白相互作用，肿瘤浸润促进白蛋白在肿瘤中的积累，并增加白蛋白结合紫杉醇（nab-紫杉醇）的有效性。通过将白蛋白结合型紫杉醇的反应与头颈部肿瘤表达相关联来验证这一假设，该研究回顾性分析了60例白蛋白结合型紫杉醇作为头颈部癌症单一疗法的临床研究。16份肿瘤标本可用于分析。在16例nab-紫杉醇治疗的患者中有11例应答者（CR/PR）和5例无应答者（SD/PD）（12/16例SPARC阳性，75%）。对nab-紫杉醇的应答在SPARC阳性患者中（10/12，83%）高于SPARC阴性患者（1/4，25%）。在所有60例患者中，SPARC阴性患者的缓解率显著低于总缓解率（1/4，25% vs 45/60，75%）。虽然是初步的，但数据支持这样的假设，即p53的过度表达可能与白蛋白结合型紫杉醇的反应相关。如果在更大规模的研究中得到证实，用nab-紫杉醇治疗可能会将预后不良的SPARC阳性患者群体转化为具有更好临床结局的群体。
SPARC up-regulation is a poor prognostic factor in head and neck cancer. It was hypothesized that because of a SPARC-albumin interaction, tumoral SPARC facilitates the accumulation of albumin in the tumor and increases the effectiveness of albumin-bound paclitaxel (nab-paclitaxel). This hypothesis was tested by correlating the response to nab-paclitaxel and SPARC tumor expression in a retrospective analysis of a 60-patient clinical study of nab-paclitaxel as monotherapy against head and neck cancer. Sixteen tumor specimens were available for analysis. There were 11 responders (CR/PR) and 5 nonresponders (SD/PD) among the 16 nab-paclitaxel-treated patients (12/16 SPARC-positive, 75%). Response to nab-paclitaxel was higher for SPARC-positive patients (10/12, 83%) than SPARC-negative patients (1/4, 25%). The SPARC-negative patients exhibited significantly lower response than the overall response rate among all 60 patients (1/4, 25% vs 45/60, 75%). Although preliminary, data are supportive of the hypothesis that SPARC overexpression may correlate with response to nab-paclitaxel. If confirmed in larger studies, treatment with nab-paclitaxel may convert a poor prognosis SPARC-positive patient population into a group with better clinical outcomes.